Cognis licenses further active ingredients for weight management and heart health from InterMed Discovery
Cognis and InterMed Discovery (IMD) announced that Cognis has exclusively licensed two further product candidates from IMD: one is a new functional ingredient, which shows promise in the area of weight management and the other provides beneficial effects for heart health.
Using its unique technology platform, IMD can correlate chemical structures with biological activity on a broad scale. During their ongoing collaboration, Cognis and IMD have utilized this technology platform to identify novel active functional ingredients for specific food applications. The latest breakthrough has led to the discovery of two natural product candidates that are consistent with the global trends for active weight management and a proactive approach to heart health.
Cognis has now licensed two active ingredients supporting weight management from IMD, the first of which was licensed in October 2008. The second new ingredient represents a cardiovascular product candidate for hearth health, which has shown interesting efficacy results in in vitro tests. Cognis plans to carry out preclinical studies later this year.
Under the terms of a licensing agreement, Cognis will take the lead in the product development process and will be responsible for marketing any resulting products. In return, InterMed Discovery will receive an upfront payment and royalties.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
